VYGR
Voyager Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.51
+3.85%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$216.28M
MomentumView details →
1D Return
+3.85%
YTD Return
−12.70%
RSI (14)
53.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.3x
Market Cap
$216.28M
RSI (14)
53.8
MomentumView details →
1D Return
+3.85%
YTD Return
−12.70%
SummaryUpdated Jun 1, 2026
Voyager Therapeutics, Inc. (NASDAQ:VYGR) is a clinical-stage gene therapy company founded in 2013 and headquartered in Cambridge, Massachusetts. The company went public in November 2015 and has since focused on developing innovative treatments for neurological diseases using advanced gene therapy technologies. Voyager specializes in creating adeno-associated virus (AAV) gene therapies that can cross the blood-brain barrier to deliver therapeutic payloads directly to the central nervous system, addressing some of the most challenging neurodegenerative conditions including Parkinson's disease, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS).
Similar companies
Latest newsMore news →
Dimensional Fund Advisors LP reduced its stake in Voyager Therapeutics, Inc. by 19.3%, selling 208,931 shares during the quarter, leaving 875,568 shares, as disclosed in a 13F filing.23d agoVoyager Therapeutics reported Q2 2026 financial results with revenue of $3.2 million, a net loss of $24.5 million, and diluted EPS of -$0.40.30d ago